Dyserythropoiesis associated with a myelodysplastic syndrome can result in anemia. Certain findings can help identify the patients who are likely to respond to therapy with human recombinant erythropoietin. The authors are from Stockholm and Sundsvall in Sweden.

To read more or access our algorithms and calculators, please log in or register.